VCI Global Revises Equity Agreement with 102% Premium Pricing, Enhancing Strategic Flexibility
Amended Terms with Alumni Capital Reinforce Disciplined Capital Deployment and Long-Term Growth Priorities
KUALA LUMPUR, Malaysia, May 22, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) ('VCI Global'), a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, today announced a significant amendment to its equity line agreement with Alumni Capital LP ('Alumni Capital'). The revised terms underscore VCI Global's disciplined capital strategy and reinforce its commitment to long-term shareholder value.
Under the revised terms, any future equity issuance to Alumni Capital will be priced at 102% of the lowest trading price over the preceding five trading days, a notable improvement from the previous pricing of 85% of the same reference period. This shift reflects increased institutional confidence in VCI Global's growth trajectory and introduces a more shareholder-aligned capital structure.
With these improved terms, the capital agreement now serves as a powerful financial lever, a liquidity reserve that enables the Company to capitalize on strategic acquisitions, accelerate platform initiatives, or respond swiftly to market dynamics. Importantly, the Company retains full discretion over drawdowns, ensuring capital is deployed only when conditions are optimal. VCI Global remains focused on disciplined, high-impact growth and long-term value creation.
Key Terms of the Amended Facility
Premium-Based Pricing: Future equity tranches will be priced at 102% of the lowest five-day trading price, replacing the previous 85% pricing model. This reduces dilution and strengthens shareholder alignment.
Strategic Control: VCI Global retains the right, but not the obligation, to access the approximately US$112 million facility, enabling capital to be utilized only when strategically beneficial.
Supports Scalable Growth: The revised terms complement VCI Global's aggressive expansion into AI infrastructure, cybersecurity, and capital markets advisory, while preserving financial flexibility.
'This revised pricing framework demonstrates a strong investor conviction in our long-term trajectory. It ensures that we retain the flexibility to act decisively while significantly minimizing dilution for existing shareholders. With these terms in place, we are better positioned to accelerate execution, protect value, and unlock scalable impact across our verticals,' said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.
About VCI Global Limited
VCI Global is a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy. With a strong presence in Asia, Europe, and the United States, VCI Global is committed to driving technological innovation, sustainable growth, and financial excellence across multiple industries.
For more information on the Company, please log on to https://v-capital.co/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission ('SEC'). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.
CONTACT INFORMATION:
For media queries, please contact:
VCI GLOBAL LIMITEDenquiries@v-capital.coSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
VEON and Engro Corporation Complete Pioneering Infrastructure Partnership in Pakistan
Islamabad and Dubai, June 3, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator ('VEON' or 'the Company'), announces that it has successfully closed the partnership for the pooling and management of telecommunications infrastructure assets in Pakistan with Engro Corporation Limited ('Engro Corp'). VEON's infrastructure assets housed under Deodar (Private) Limited have now vested into Engro Connect, a subsidiary of Engro Corp. VEON's digital operator Jazz will continue to lease Deodar's extensive infrastructure for the provision of nationwide mobile voice and data services under a long-term partnership agreement. "Completion of this partnership marks another milestone in the execution of our asset-light strategy. Thanks to the visionary approach of Pakistani authorities, which enabled the successful completion of this partnership, Jazz can now further accelerate its transformation into a services company, with a connectivity-powered digital portfolio spanning financial services, entertainment, healthcare, and enterprise services for both consumers and businesses. We look forward to a fruitful partnership with Engro Corp and to contributing to our shared mission of strengthening Pakistan's digital economy,' said Kaan Terzioglu, VEON Group CEO and Chairman of Jazz Board. The scheme of arrangement was completed at an enterprise value of USD 562.7 million. The partnership, which was originally announced on December 5, 2024, obtained regulatory approvals in May 2025. About VEON VEON is a Nasdaq-listed digital operator that provides converged connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world's population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. For more information visit: About Jazz Jazz is Pakistan's leading digital operator with over 71.5 million cellular subscribers and 73 million MAUs of digital services as of Q4 2024. Jazz offers the most extensive portfolio of digital services in Pakistan, including JazzCash, the country's leading fintech; Garaj, the largest onshore cloud and cybersecurity platform; and Tamasha, Pakistan's largest homegrown OTT video streaming and entertainment platform. About Engro Corporation Limited Engro Corporation is a diversified Pakistani conglomerate that strives to solve pressing issues through its portfolio of businesses. It has developed businesses across the verticals of energy and related infrastructure, petrochemicals, food and agriculture, telecommunication infrastructure, and international trading, over a period of 50+ years. Many of these pioneering businesses have been established in collaboration with global partners including IFC, Royal Vopak, Royal FrieslandCampina, CMEC and others. To learn more about Engro Corporation, please visit Disclaimer This release contains 'forward-looking statements', as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts, and include statements relating to, among other things, VEON's investment plans, digital products, business plans and commercial partnerships. Forward-looking statements are inherently subject to risks and uncertainties, many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update, except as required by U.S. federal securities laws, any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events. VEONHande Asik Group Director of Communicationspr@
Yahoo
30 minutes ago
- Yahoo
Asia-Pacific Pediatric Interventional Cardiology Industry Report 2025-2033: Insights Into Markets, Shares, Companies, Trends, Growth Opportunities and More
Driving factors include rising congenital heart defect cases, healthcare advancements, governmental support, and demographic trends in China and India Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pediatric Interventional Cardiology Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to reach US$ 1.52 billion by 2033 from US$ 829.09 million in 2024, with a CAGR of 7.01% from 2025 to 2033. Increased cases of congenital heart defects, improved healthcare infrastructure, increased public awareness, technological innovations, encouraging governmental support, and increasing child populations - especially in developing countries such as China and India - are all contributing to the Asia-Pacific pediatric interventional cardiology market. The specialty branch of pediatric interventional cardiology is committed to minimally invasive diagnosis and treatment of cardiac ailments in neonates, children, and adolescents. Interventional cardiologists perform procedures such as fixing congenital heart defects, opening narrowed valves or arteries, and closing septal defects with catheters inserted via blood vessels instead of open heart surgery. Typically, imaging devices such as echocardiography or fluoroscopy guide these operations. In comparison to surgery, the technique offers faster recovery, less time in the hospital, and fewer complications. To address congenital and acquired cardiac issues and improve the quality of life of young children, pediatric interventional cardiology is a must. Several key drivers are responsible for the significant growth of the Asia-Pacific pediatric interventional cardiology market. The demand for better pediatric cardiac care is fueled by the increasing prevalence of congenital heart diseases, particularly in populous countries such as China and India. Availability of minimally invasive interventions is being enhanced by improved healthcare infrastructure, increased government support, and increased investment in medical technology. In addition, the availability of skilled healthcare professionals, increased health insurance coverage, and improved parental awareness are all contributing to market growth. Adoption of pediatric interventional cardiology in the Asia-Pacific region is being led by advances in diagnostic equipment and interventional devices, which also facilitate enhanced outcomes. The Asia-Pacific Pediatric Interventional Cardiology Market is expected to grow enormously because of the rise in the number of congenital heart abnormalities (CHDs). The rate of babies born with congenital heart defects has increased enormously because of the rise in birth rates in countries like China and India. Due to advances in diagnostic technologies such as newborn screening and fetal echocardiography, early identification has increased. As parents and physicians become increasingly aware, more children are being diagnosed early and referred for treatment. Open cardiac surgery is less required when these issues are treated with minimally invasive methods offered by pediatric interventional cardiology. Advanced pediatric cardiac interventions remain in high demand in the Asia-Pacific region because of the increasing incidence of congenital heart disease and greater access to specialist care. The Asia-Pacific Pediatric Interventional Cardiology Market is likely to grow tremendously with the enhanced healthcare infrastructure. In countries such as China, India, and Southeast Asia, economic growth and urbanization have led to massive investments in healthcare systems. Availability of quality interventional therapy to children with heart issues has been enhanced through the expansion of specialist cardiac centers, the presence of state-of-the-art medical technology, and improved training of pediatric cardiologists. Treatment outcomes and hospital capacities are being enhanced through international cooperation and public-private alliances. Demand is also being driven by the expansion of digital health platforms and telemedicine, which are bridging the gap between rural communities and specialist cardiac care. In Asia-Pacific, increasing numbers of children are enjoying early diagnosis and minimally invasive cardiac surgery as healthcare systems improve. Asia-Pacific Pediatric Interventional Cardiology Market is anticipated to grow enormously due to technological advances in minimally invasive technology. Pediatric cardiac therapy has been revolutionized by leaps in imaging modalities, catheter-based intervention, and downsized devices. Congenital heart disease now can be targeted exactly and effectively with no need for open-heart surgery due to these technologies that reduce hospital stay, accelerate recovery, and reduce risk of complications. The development of smaller, child-specific devices such as balloons, stents, and occluders has enhanced the safety and effectiveness of newborn and young children's treatments. With growing investments in healthcare innovation, countries in the Asia-Pacific region are adopting these advanced tools at a growing pace. Treatment options and market expansion are being significantly enhanced by the incorporation of technology in pediatric cardiology as it becomes increasingly accessible and affordable. One major obstacle facing the Asia-Pacific pediatric interventional cardiology market is the high cost of therapy. Many families, especially those in lower-income areas, cannot afford the high costs of advanced operations, specialist equipment, and hospital stays. Even though insurance coverage is growing, it frequently falls short of covering all expenses, particularly in developing nations. The overall development and efficacy of pediatric interventional cardiology in the area are hampered by this financial barrier, which restricts children with congenital heart abnormalities' access to prompt, life-saving therapies. The Asia-Pacific Pediatric Interventional Cardiology Market faces many challenges, one of which is limited access to specialized care. Advanced pediatric cardiac centers are few and far between, and healthcare infrastructure is sometimes inadequate in rural and isolated places. Timely identification and treatment of congenital cardiac abnormalities are hindered by this lack of access. Long commutes to receive care may be necessary for families in underprivileged areas, further postponing intervention. This discrepancy in access to healthcare poses serious obstacles to fair treatment throughout the area. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $829.09 Million Forecasted Market Value (USD) by 2033 $1.52 Billion Compound Annual Growth Rate 7% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Pediatric Interventional Cardiology Market5.1 Historical Market Trends5.2 Market Forecast6. Asia-Pacific Pediatric Interventional Cardiology Market Share Analysis6.1 By Device Type6.2 By Procedure6.3 By End Use6.4 By Countries7. Device Type7.1 Transcatheter Heart Valves7.2 Atherectomy Devices7.3 Catheters7.4 Closure Devices7.5 Balloons7.6 Stents7.7 Others8. Procedure8.1 Catheter-based Valve Implantation8.2 Congenital Haert Defect Correction8.3 Angioplasty8.4 Coronary Thrombectomy8.5 Others9. End Use9.1 Hospitals9.2 Ambulatory Surgical Centers9.3 Others10. Countries10.1 China10.2 Japan10.3 India10.4 South Korea10.5 Thailand10.6 Malaysia10.7 Indonesia10.8 Australia10.9 New Zealand10.10 Rest of Asia-Pacific11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Abbott Laboratories Inc.13.1.1 Overviews13.1.2 Key Person13.1.3 Recent Developments & Strategies13.1.4 Revenue Analysis13.2 Boston Scientific Corporation13.3 Medtronic PLC13.4 B. Braun13.5 Biosensors International Group, Ltd.13.6 Siemens AG13.7 Cardinal Health Inc.13.8 Terumo Medical CorporationFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Pollen Allergy Market Analysis Report 2025: Innovative Strategies in Pollen Allergy Diagnosis and Treatment Emerge - Global Forecast to 2030
This comprehensive report delivers insights into market trends, drivers, and forecasts, covering recent tariff developments affecting the industry. Pollen allergies, increasingly prevalent worldwide, are exacerbated by urbanization, climate change, and pollution. Advances in diagnosis and treatment, including molecular diagnostics and allergen immunotherapy, are shaping the market. With regions like Asia-Pacific driving growth due to healthcare investments, the report explores comprehensive market analysis, competitive landscapes, emerging trends, and regional dynamics, guiding strategic business decisions. Pollen Allergy Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to global market for Pollen Allergy was valued at US$5.4 Billion in 2024 and is projected to reach US$6.7 Billion by 2030, growing at a CAGR of 3.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pollen Allergy market. Global Pollen Allergy Market - Key Trends & Drivers SummarizedWhy Is Pollen Allergy Emerging as a Global Public Health Concern?Pollen allergy, medically referred to as seasonal allergic rhinitis or hay fever, is becoming a widespread public health issue affecting hundreds of millions globally. Characterized by symptoms such as nasal congestion, sneezing, watery eyes, and respiratory discomfort, the condition results from hypersensitivity of the immune system to pollen from grasses, weeds, and trees. The growing prevalence of pollen-induced allergies is closely linked to urbanization, climate change, increased air pollution, and extended pollen seasons - factors that together intensify allergen exposure and areas are reporting higher allergy rates due to the "urban heat island" effect and the proliferation of allergenic plant species in landscaping. Moreover, industrial emissions and diesel particulates interact with pollen grains, increasing their allergenicity and aggravating symptoms in sensitive populations. This trend is not limited to developed countries - rising diagnosis rates in Asia-Pacific, Latin America, and parts of Africa highlight that pollen allergy is fast becoming a global epidemic, particularly among children, adolescents, and working-age adults who suffer significant quality-of-life disruptions and productivity Are Diagnosis and Therapeutic Strategies Evolving for Effective Symptom Management?The diagnosis of pollen allergy traditionally involves skin prick tests, blood IgE assays, and clinical history analysis. However, recent developments in molecular diagnostics now enable allergen component-resolved diagnostics (CRD), which offer precise identification of the specific proteins within pollen that trigger hypersensitivity reactions. CRD is helping to tailor immunotherapy approaches and minimize cross-reactivity, especially in poly-sensitized individuals reacting to multiple environmental management includes antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and decongestants, with growing interest in combination therapies for multi-symptom control. Allergen immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT), remains the only long-term disease-modifying treatment. AIT desensitizes the immune system through controlled allergen exposure and is gaining popularity due to its potential to prevent the progression of allergic rhinitis to asthma. Over-the-counter (OTC) allergy remedies, air filtration devices, and mobile health apps for pollen forecasting are further supporting symptom avoidance and self-management among patients Is Innovation Taking Shape Across Diagnostics, Delivery Formats, and Regional Care Models?Innovation in the pollen allergy market is not confined to pharmaceuticals but spans across diagnostics, delivery systems, and digital therapeutics. Needle-free delivery devices for immunotherapy and metered-dose nasal sprays are enhancing patient adherence and reducing discomfort. Biotech firms are developing hypoallergenic recombinant pollen allergens and adjuvant-enhanced immunotherapy formulations for improved efficacy and reduced adverse reactions. These technologies are creating a shift toward personalized allergy care, especially in high-income enabled care models are also gaining ground. Wearable air quality sensors, smartphone apps integrated with pollen dispersion models, and teleconsultation services are empowering patients to anticipate triggers and access timely medical support. Regionally, Europe remains at the forefront in allergy research and treatment accessibility, while North America shows strong commercial uptake of OTC and immunotherapy products. Asia-Pacific is emerging as a high-potential market, driven by rising allergic disease awareness, urban air quality challenges, and increasing healthcare investments. Governments are initiating school and workplace screening programs to identify and manage allergy-prone populations more Driving the Accelerated Growth of the Global Pollen Allergy Market?The growth in the global pollen allergy market is driven by several factors, including the rising global incidence of allergic rhinitis, worsening air quality, and longer pollen seasons linked to climate change. Increasing environmental awareness, improved allergy diagnostics, and broader availability of OTC antihistamines and immunotherapy solutions are further contributing to market expansion. Healthcare systems are also recognizing the socioeconomic impact of allergic rhinitis, which leads to missed school days, absenteeism, and comorbidities like sinusitis and advancements in allergy testing, predictive modeling, and digital health management are enhancing early diagnosis and sustained care. Pharmaceutical innovations in non-sedating antihistamines, nasal corticosteroid combinations, and biologics are improving symptom control and reducing patient dropout from long-term treatment regimens. With growing emphasis on preventive healthcare, environmental control measures, and personalized immunotherapy, the pollen allergy market is expected to witness robust growth, especially as climate change continues to alter allergen distribution patterns and intensify the global allergic disease Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Aimmune Therapeutics, Alcon Inc., ALK-Abello A/S, Allergopharma and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$4.4 Billion by 2030 with a CAGR of a 4.2%. The Consumables segment is also set to grow at 3.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 7.0% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Instruments, Consumables, Services) Therapeutics Drug Class (Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, Immunotherapy) Allergen Type (Food, Inhaled, Drug, Other Allergen Types) End-Use (Diagnostic Laboratories, Hospitals, Other End-Uses) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 498 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.4 Billion Forecasted Market Value (USD) by 2030 $6.7 Billion Compound Annual Growth Rate 3.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Pollen Allergy - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Prevalence of Seasonal Allergic Rhinitis Spurs Growth in the Pollen Allergy Management Market Expansion of Urbanization and Air Pollution Throws the Spotlight on Heightened Allergen Sensitization Development of Non-Sedating Antihistamines and Long-Acting Therapies Enhances Daily Symptom Control Growth in Immunotherapy and SLIT (Sublingual Immunotherapy) Adoption Expands Treatment Landscape Innovation in Air Filtration, Pollen Barriers, and Nasal Sprays Drives Preventive Allergy Management Increasing Demand for OTC Remedies and Natural Allergy Relief Products Fuels Consumer Healthcare Sales Collaboration With ENT Specialists and Allergy Clinics Strengthens Integrated Treatment Approaches Surge in Home and Portable Air Quality Devices Propels Pollen Monitoring Integration Focus on Rapid Allergen Diagnostic Testing and Home Kits Enhances Consumer Empowerment Growth in Biologics and Monoclonal Antibody Therapy Expands Options for Severe Allergy Management Advances in Allergen Mapping and Pollen Forecasting Drive Personalized Treatment Solutions Expansion of Mobile Health and Allergy Management Apps Spurs Digital Health Adoption in Allergy Control Participation in Regulatory Guidelines for Allergy Medication Labeling Strengthens Safety Profiles Increasing Awareness of Cross-Reactivity and Food-Pollen Syndrome Drives Demand for Educational Resources Entry Into Pediatric Allergy Management Market Enhances Age-Specific Treatment Accessibility Rising Popularity of Nasal Filters, HEPA Masks, and Wearables Strengthens Non-Pharmacological Product Category Investment in Botanical and Non-Corticosteroid Therapeutics Enhances Natural Remedy Pipeline Expansion of Allergy Care in Emerging Markets Through E-Pharmacy and Telehealth Platforms Supports Access Differentiation Through Symptom Tracker Integration and Adherence Tools Improves Chronic Case Outcomes Global Climate Change Patterns Alter Pollen Seasons, Increasing Duration and Intensity of Allergic Episodes FOCUS ON SELECT PLAYERS AbbVie Inc. Aimmune Therapeutics Alcon Inc. ALK-Abello A/S Allergopharma Allergy Therapeutics ASIT Biotech SA Bayer AG Biomay AG bioMerieux SA Circassia Pharmaceuticals DBV Technologies Genentech Inc. GlaxoSmithKline plc HAL Allergy Group HOB Biotech Group Corp Ltd Johnson & Johnson LETIPharma Merck KGaA Stallergenes Greer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pollen Allergy Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
